Literature DB >> 18367111

Exploring causes for declining prostate cancer mortality rates in the United States.

Janet L Colli1, Christopher L Amling.   

Abstract

OBJECTIVES: Prostate cancer mortality rates in the U.S.A. increased in the late 1980s and declined from 1993 until 2003. The purpose of this study is to compare declining prostate cancer mortality rates among states with independent variables that may have an association to explore causes for the decline. METHODS AND MATERIALS: Annual rates of prostate cancer mortality for men over 50 were obtained from the National Vital Statistic System public use data file for states for individual years from 1993 to 2003. The annual rate of prostate cancer mortality decline for each state was calculated by the Joinpoint Regression Program (Statistical Research and Applications Branch of NCI). Annual rates of prostate cancer decline were cross-correlated to state levels of PSA screening, health insurance coverage, obesity, physical inactivity, diabetes, and high cholesterol for males from 45 to 64.
RESULTS: Declining prostate cancer mortality rates for white males correlated with high cholesterol levels (R = -0.42, P = 0.002) and PSA screening levels (R = -0.28, P = 0.05). Declining prostate cancer mortality rates for black males correlated with health insurance coverage (R = -0.43, P = 0.03).
CONCLUSIONS: Declining prostate cancer mortality rates are weakly associated with increased PSA screening for white males but there was no association for black males, possibly because blacks have less access to medical care. The strong inverse correlation between declining prostate cancer mortality rates and levels of white males with high cholesterol levels was unexpected but may be associated with the widespread use of cholesterol reducing medications (statins), which are hypothesized to reduce prostate cancer risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367111     DOI: 10.1016/j.urolonc.2007.05.016

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  6 in total

1.  Attitudes and knowledge of primary care physicians regarding prostate cancer screening.

Authors:  Kelly Johnson; Myron Chang; Yilun Sun; Makito Miyake; Charles J Rosser
Journal:  J Cancer Educ       Date:  2013-12       Impact factor: 2.037

Review 2.  A review of statin use and prostate cancer.

Authors:  Doreen Pon; Andrew Abe; Eric K Gupta
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

Review 3.  The current evidence on statin use and prostate cancer prevention: are we there yet?

Authors:  Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland
Journal:  Nat Rev Urol       Date:  2016-10-25       Impact factor: 14.432

4.  Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4.

Authors:  David Cervi; Brian Pak; Natalie A Venier; Linda M Sugar; Robert K Nam; Neil E Fleshner; Laurence H Klotz; Vasundara Venkateswaran
Journal:  BMC Cancer       Date:  2010-06-04       Impact factor: 4.430

Review 5.  Chemoprevention of prostate cancer: what can be recommended to patients?

Authors:  Janet L Colli; Christopher L Amling
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

6.  The routine use of prostate-specific antigen for early detection of cancer prostate in India: Is it justified?

Authors:  Deepak Dubey
Journal:  Indian J Urol       Date:  2009-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.